Study guide

Section 2.1: Medicinal Chemistry & Structure-Activity Relationships (SAR)

Saudi Pharmacist Licensure Examination SPLE - Pharmacist

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

Section 0.1: About the Saudi Pharmacist Licensure Examination (SPLE) Section 0.2: How to Study and Prep for the SPLE

2 Chapter 1: Basic Biomedical Sciences

Section 1.1: Human Physiology & Pathophysiology Foundations Section 1.2: Medical Biochemistry & Enzymology Section 1.3: Medical Microbiology & Immunology Section 1.4: Molecular Genetics & Pharmacogenomics Foundations

3 Chapter 2: Pharmaceutical Sciences

Section 2.1: Medicinal Chemistry & Structure-Activity Relationships (SAR) Section 2.2: Drug ADME (Absorption, Distribution, Metabolism, Excretion) Section 2.3: General Pharmacology: Mechanisms of Drug Action Section 2.4: General Toxicology: Overdose, Antidotes & Adverse Drug Reactions (ADRs) Section 2.5: Pharmacognosy: Natural Products & Dietary Supplements Section 2.6: Basic Pharmaceutics & Dosage Form Design Section 2.7: Biopharmaceutics & Drug Delivery Systems Section 2.8: Applied Pharmacokinetics (PK): One-Compartment Models Section 2.9: Non-linear and Multi-compartment Pharmacokinetics Section 2.10: Sterile Compounding: Techniques & Quality Standards Section 2.11: Non-sterile Compounding & Product Formulation Section 2.12: Pharmaceutical Calculations: Dosing and Strengths Section 2.13: Pharmaceutical Calculations: Dilutions and Reconstitution Section 2.14: Pharmaceutical Calculations: Osmolarity, Milliequivalents, and Alligations

4 Chapter 3: Social, Behavioral, and Administrative Sciences

Section 3.1: Saudi Arabian Healthcare System & Public Health Policies Section 3.2: Pharmacoepidemiology & Post-Marketing Drug Surveillance Section 3.3: Pharmacovigilance & Drug Safety Monitoring in Saudi Arabia Section 3.4: Pharmacoeconomic Principles & Cost-Benefit Analysis Section 3.5: Pharmacy Management, Inventory, and Operations Section 3.6: Saudi Pharmacy Law & SFDA Regulations Section 3.7: Biostatistics, Clinical Trial Design & Literature Evaluation Section 3.8: Professional Ethics, Communication, and Dispensing Systems

5 Chapter 4: Clinical Sciences

Section 4.1: Drug Information Services & Evidence-Based Medicine Section 4.2: Clinical Pharmacokinetics & Therapeutic Drug Monitoring (TDM) Section 4.3: Clinical Pharmacogenomics & Personalized Therapeutics Section 4.4: Disease Prevention, Wellness, and Immunization Schedules Section 4.5: Patient Assessment & Physical Examination Interpretation Section 4.6: Clinical Pharmacology: Cardiovascular Disorders Section 4.7: Clinical Pharmacology: Renal & Urological Disorders Section 4.8: Clinical Pharmacology: Respiratory & Pulmonary Disorders Section 4.9: Clinical Pharmacology: Endocrine & Metabolic Disorders Section 4.10: Clinical Pharmacology: Infectious Diseases & Antimicrobial Stewardship Section 4.11: Clinical Pharmacology: Neurological & Psychiatric Disorders Section 4.12: Clinical Pharmacology: Oncology, Immunology, and Hematology Section 4.13: Clinical Pharmacology: Gastrointestinal & Hepatic Disorders Section 4.14: Therapeutic Decision-Making in Special Populations (Geriatrics, Pediatrics, Pregnancy, Lactation)

Section 2.1: Medicinal Chemistry & Structure-Activity Relationships (SAR)

Key Takeaways Explain This Topic AI

The strained 4-membered beta-lactam ring is the active pharmacophore of penicillins and cephalosporins, which covalently inactivates PBPs.

Bulky side chains on beta-lactams (e.g., in oxacillin) sterically hinder beta-lactamase attack, while alpha-amino groups (e.g., in amoxicillin) enhance Gram-negative porin penetration.

NSAIDs require an acidic carboxylate center to form an essential ionic bond with Arginine-120 in the cyclooxygenase active site.

The 3,5-dihydroxyheptanoic acid moiety of statins mimics the tetrahedral HMG-CoA transition state, competitively inhibiting HMG-CoA reductase.

Passive membrane permeability requires drug molecules to be in their un-ionized, lipophilic state, whereas water solubility is enhanced by ionization.

Last updated: July 2026

  • Section 2.1: Medicinal Chemistry & Structure-Activity Relationships (SAR)
  • Introduction to Medicinal Chemistry in the SPLE

Medicinal chemistry combines organic chemistry, biochemistry, and pharmacology to explain how chemical structure governs a drug's pharmacodynamic (what the drug does to the body) and pharmacokinetic (what the body does to the drug) properties. For the Saudi Pharmacist Licensure Examination (SPLE), candidates must master how functional groups influence drug ionization, solubility, receptor binding, and the structure-activity relationships (SAR) of key classes such as beta-lactams, non-steroidal anti-inflammatory drugs (NSAIDs), and statins.

Functional Groups and Physicochemical Properties

Drug molecules are composed of functional groups attached to a carbon skeleton. These groups determine the overall electronic distribution, steric bulk, and solubility of the drug. They are categorized based on their acid-base character:

Acidic Functional Groups: These groups can donate a proton, becoming negatively charged (ionized) at alkaline pH. Examples include carboxylic acids (e.g., ibuprofen, pKa ≈ 4.4), sulfonamides (e.g., sulfamethoxazole, pKa ≈ 6.0), phenols (e.g., acetaminophen, pKa ≈ 9.9), and imides.

Basic Functional Groups: These groups can accept a proton, becoming positively charged (ionized) at acidic pH. Examples include aliphatic primary, secondary, and tertiary amines (e.g., albuterol, pKa ≈ 9.3), aromatic amines, and imidazoles.

Neutral Functional Groups: These groups do not ionize at physiological pH. Examples include amides, esters, ethers, alcohols, and ketones. While neutral, they contain polar atoms (like oxygen and nitrogen) that can participate in hydrogen bonding, enhancing water solubility.

  • Functional Group Acid/Base Character Typical pKa Range Example Drug
  • Carboxylic Acid Weak Acid 3.0 - 5.0 Ibuprofen, Diclofenac
  • Sulfonamide Weak Acid 5.0 - 8.0 Sulfamethoxazole
  • Phenol Weak Acid 9.0 - 10.5 Acetaminophen
  • Aliphatic Amine Weak Base 8.5 - 10.5 Diphenhydramine
  • Aromatic Amine Weak Base 3.0 - 5.0 Benzocaine
  • Imidazole Weak Base 6.0 - 7.0 Ketoconazole
  • Drug Ionization and Solubility

The ionization state of a drug is a critical determinant of its ability to cross biological membranes and dissolve in aqueous fluids. The degree of ionization is calculated using the Henderson-Hasselbalch equation :

For weak acids: p H = p K a + log ⁡ ( [ A − ] [ H A ] ) where [ A − ] is ionized, and [ H A ] is un-ionized. pH = pK_a + \log\left(\frac{[A^-]}{[HA]}\right) \quad \text{where } [A^-] \text{ is ionized, and } [HA] \text{ is un-ionized.} p H = p K a ​ + lo g ( [ H A ] [ A − ] ​ ) where [ A − ] is ionized, and [ H A ] is un-ionized.

For weak bases: p H = p K a + log ⁡ ( [ B ] [ B H + ] ) where [ B ] is un-ionized, and [ B H + ] is ionized. pH = pK_a + \log\left(\frac{[B]}{[BH^+]}\right) \quad \text{where } [B] \text{ is un-ionized, and } [BH^+] \text{ is ionized.} p H = p K a ​ + lo g ( [ B H + ] [ B ] ​ ) where [ B ] is un-ionized, and [ B H + ] is ionized.

Lipid Solubility (Membrane Permeation): Cell membranes are highly lipophilic lipid bilayers. Passive diffusion across these membranes requires the drug to be in its neutral, un-ionized form. Consequently, a weak acid is best absorbed in acidic environments (e.g., the stomach) where it remains protonated (un-ionized). Conversely, a weak base is best absorbed in basic environments (e.g., the duodenum and jejunum) where it remains unprotonated (un-ionized).

Aqueous Solubility (Dissolution): The ionized form of a drug is highly polar and interacts strongly with water molecules via ion-dipole bonds, enhancing water solubility. The Saudi Food and Drug Authority (SFDA) evaluates the salt forms of drugs (e.g., hydrochloride salts of bases, sodium salts of acids) during registration, as these salts facilitate dissolution and rapid systemic absorption.

Drug-Receptor Interactions

To elicit a biological effect, a drug must bind to its target receptor. This binding is stabilized by various chemical bonds, ranked by their strength:

Covalent Bonds (Strength: >40 kcal/mol): The strongest drug-receptor interaction. It involves the sharing of electrons and is usually irreversible under physiological conditions. Examples include aspirin acetylating the active site serine of cyclooxygenase (COX), and organophosphate nerve agents phosphorylating acetylcholinesterase.

Ionic (Electrostatic) Bonds (Strength: 5 - 10 kcal/mol): Occur between oppositely charged groups (e.g., a protonated amine on the drug and a carboxylate side chain of an aspartate or glutamate residue on the receptor). These are highly important for initial drug-receptor attraction due to their long-range action.

Hydrogen Bonds (Strength: 2 - 7 kcal/mol): Formed between an electronegative atom (oxygen, nitrogen) acting as a hydrogen acceptor and a hydrogen atom bound to another electronegative atom acting as a donor. Though individually weak, multiple hydrogen bonds provide high specificity and binding affinity.

Hydrophobic Interactions (Strength: 1 - 3 kcal/mol): Driven by the tendency of nonpolar regions of a drug (like aromatic rings or alkyl chains) to avoid water and associate with lipophilic pockets on the receptor.

Van der Waals Forces (Strength: 0.5 - 1 kcal/mol): Weak, short-range attractions between temporary dipoles in non-polar molecules.

  • Structure-Activity Relationships (SAR) of Major Classes
  • 1. Beta-Lactam Antibiotics

The beta-lactam class (penicillins, cephalosporins, carbapenems, monobactams) target penicillin-binding proteins (PBPs) to inhibit bacterial cell wall synthesis.

The Beta-Lactam Ring: The 4-membered cyclic amide is the core pharmacophore. The high ring strain (90-degree bond angles instead of the normal 120-degree angles of an amide) makes the carbonyl carbon highly susceptible to nucleophilic attack by the serine residue in the active site of PBPs, leading to covalent inactivation.

Fused Ring Systems: Penicillins contain a fused 5-membered thiazolidine ring (penam core), whereas cephalosporins possess a fused 6-membered dihydrothiazine ring (cephem core). The cephalosporin core has less ring strain, making it inherently more stable than penicillins.

Acylamino Side Chain (R-group) Modifications:

Penicillin G (benzylpenicillin) has a simple benzyl side chain, making it highly susceptible to gastric acid hydrolysis and beta-lactamases.

Amoxicillin and Ampicillin introduce an amino group at the alpha position of the side chain. This increases hydrophilicity, allowing these drugs to pass through the porin channels of Gram-negative outer membranes.

Methicillin, Oxacillin, and Nafcillin incorporate bulky, sterically hindered aromatic side chains. This bulk prevents staphylococcal beta-lactamase (penicillinase) from accessing the beta-lactam carbonyl carbon, providing resistance against these enzymes.

Piperacillin incorporates a polar ureido group, extending its spectrum of activity to include Pseudomonas aeruginosa .

2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs act by inhibiting cyclooxygenase (COX) enzymes, preventing the synthesis of inflammatory prostaglandins.

The Acidic Center: Almost all classic NSAIDs possess an acidic functional group (typically a carboxylic acid, e.g., ibuprofen, ketoprofen, diclofenac). This carboxylate group mimics the carboxylate of arachidonic acid (the natural substrate) and forms a critical ionic bond with the cationic guanidinium group of Arginine-120 in the COX active site.

Hydrophobic Core: An aromatic or heteroaromatic ring system is required to interact with the hydrophobic channel of the COX enzyme.

Non-Coplanarity: Two aromatic rings situated non-coplanarly (as in diclofenac, where ortho-chlorine atoms force the rings out of plane) optimize binding inside the hydrophobic pocket, significantly increasing potency.

COX-2 Selectivity: Selective COX-2 inhibitors (coxibs, e.g., celecoxib) lack the carboxylic acid group. Instead, they incorporate a rigid sulfonamide or sulfonyl group. COX-2 contains a larger active site pocket with a hydrophilic side pocket (due to a Valine substitution at position 523 instead of the bulky Isoleucine found in COX-1). The bulky sulfonamide group of celecoxib fits selectively into this COX-2 side pocket, avoiding COX-1 inhibition and reducing GI adverse effects.

3. HMG-CoA Reductase Inhibitors (Statins)

Statins competitively inhibit the rate-limiting enzyme in cholesterol biosynthesis.

The Dihydroxyheptanoic Acid Moiety: This 3,5-dihydroxyheptanoic acid (or its lactone prodrug, as in simvastatin, which is hydrolyzed in vivo to the active dihydroxy acid) is the essential pharmacophore. It structurally mimics the HMG moiety of HMG-CoA and the tetrahedral transition state formed during the reduction of HMG-CoA to mevalonate.

Lipophilic Ring System: A complex hydrophobic ring system (e.g., naphthalene in simvastatin/pravastatin; fluorophenyl/isopropyl-substituted pyrrole in atorvastatin; fluorophenyl/isopropyl-substituted pyrimidine in rosuvastatin) binds to the hydrophobic pocket of the enzyme.

Polar Substituents (Potency): Rosuvastatin and atorvastatin contain additional polar groups (such as sulfonamide and amide groups) that form extra hydrogen-bonding interactions with the enzyme's active site (specifically with Arg-590 and Ser-565). This explains their higher potency ("high-intensity statins") compared to older agents.